Screener
Collegium Pharmaceutical, Inc. COLL Azstarys — Cost
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Line item | June 30, 2026 / Cost | June 30, 2026 / Accumulated Amortization | June 30, 2026 / Carrying Amount | December 31, 2025 / Cost | December 31, 2025 / Accumulated Amortization | December 31, 2025 / Carrying Amount |
|---|---|---|---|---|---|---|
| Jornay PM | $635,000 | $(152,986) | $482,014 | $635,000 | $(111,072) | $523,928 |
| Azstarys | 635,000 | (7,480) | 627,520 | — | — | — |
| Belbuca | 360,000 | (322,305) | 37,695 | 360,000 | (284,607) | 75,393 |
| Nucynta Products | 521,170 | (521,170) | — | 521,170 | (493,478) | 27,692 |
| Symproic | 70,000 | (31,145) | 38,855 | 70,000 | (27,503) | 42,497 |
| Total intangible assets | $2,221,170 | $(1,035,086) | $1,186,084 | $1,586,170 | $(916,660) | $669,510 |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s azstarys — cost?
- Collegium Pharmaceutical, Inc. (COLL) reported azstarys — cost of $635M in Q2 2026.
- What does azstarys — cost mean?
- Reflects the direct costs associated with the production, manufacturing, and distribution of the Azstarys product. Monitoring this helps evaluate the gross margin efficiency and cost-of-goods-sold structure for this specific pharmaceutical asset.
Ask your AI about Collegium Pharmaceutical, Inc.'s azstarys — cost.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude